Tag: AXIM biotech
June 23, 2017
AXIM Biotech Applies for US Patent on Opioid Addiction Treatment
AXIM Biotechnologies applied for a patent with the United States Patent and Trademark Office involving a chewing gum composition with... January 18, 2017
AXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum
AXIM® Biotechnologies (OTC:AXIM), a world leader in cannabinoid research and development, entered a clinical trial on treating irritable bowel syndrome... January 4, 2017
AXIM® Biotech Receives Positive PK Data Results for CanChew Plus® CBD Gum
AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, received positive pharmacokinetic (PK) data results... December 6, 2016
AXIM® Biotech Receives Medical Ethical Committee Approval to Begin IBS Trial for Canchew Plus® CBDGum
AXIM® Biotechnologies today announced that it received approval from the Medical Ethical Committee of Wageningen University, The Netherlands, to begin... November 3, 2016
Medical Marijuana Publishes Product Pipeline Chart for Pharma Clinical Trials Program
Medical Marijuana, Inc. (OTC: MJNA) today announced that its investment AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader... November 1, 2016
AXIM Biotech Begins PK/PD Studies With CanChew Plus CBD Gum for IBS Symptoms
AXIM® Biotechnologies, a world leader in cannabinoid research and development, today announced that it has begun pharmacokinetic/pharmacodynamics studies with its... October 6, 2016